

Ruben P A Van Eijk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5809189/publications.pdf>

Version: 2024-02-01

64
papers

1,788
citations

361296

20
h-index

315616

38
g-index

65
all docs

65
docs citations

65
times ranked

1997
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical relevance of testing for metabolic vitamin B12 deficiency in patients with polyneuropathy. <i>Nutritional Neuroscience</i> , 2022, 25, 2536-2546.	1.5	6
2	Functional Loss and Mortality in Randomized Clinical Trials for Amyotrophic Lateral Sclerosis: To Combine, or Not to Combine—That is the Estimand. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 817-825.	2.3	5
3	Short-term effect and effect on rate of lung function decline after surgery for neuromuscular or syndromic scoliosis. <i>Pediatric Pulmonology</i> , 2022, 57, 1303-1309.	1.0	2
4	Natural history of respiratory muscle strength in spinal muscular atrophy: a prospective national cohort study. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 70.	1.2	12
5	Clinical trials in pediatric ALS: a TRICALS feasibility study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 481-488.	1.1	3
6	Joint modeling of endpoints can be used to answer various research questions in randomized clinical trials. <i>Journal of Clinical Epidemiology</i> , 2022, 147, 32-39.	2.4	2
7	Composite endpoint for ALS clinical trials based on patient preference: Patient-Ranked Order of Function (PROOF). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 539-546.	0.9	8
8	Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating procedures. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 500-507.	1.1	8
9	Characterising ALS disease progression according to El Escorial and Gold Coast criteria. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 865-870.	0.9	10
10	Correlates of Fatigability in Patients With Spinal Muscular Atrophy. <i>Neurology</i> , 2021, 96, e845-e852.	1.5	20
11	Quantification of disease progression in spinal muscular atrophy with muscle MRI—a pilot study. <i>NMR in Biomedicine</i> , 2021, 34, e4473.	1.6	19
12	Effect of Virtual Reality Gait Training on Participation in Survivors of Subacute Stroke: A Randomized Controlled Trial. <i>Physical Therapy</i> , 2021, 101, .	1.1	27
13	An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 300-307.	1.1	30
14	Pattern of muscle strength improvement after intravenous immunoglobulin therapy in multifocal motor neuropathy. <i>Muscle and Nerve</i> , 2021, 63, 678-682.	1.0	1
15	Motor unit reserve capacity in spinal muscular atrophy during fatiguing endurance performance. <i>Clinical Neurophysiology</i> , 2021, 132, 800-807.	0.7	4
16	Prognostic value of nerve ultrasonography: A prospective multicenter study on the natural history of chronic inflammatory neuropathies. <i>European Journal of Neurology</i> , 2021, 28, 2327-2338.	1.7	5
17	Innovating Clinical Trials for Amyotrophic Lateral Sclerosis. <i>Neurology</i> , 2021, 97, 528-536.	1.5	19
18	Venous creatinine as a biomarker for loss of fat-free mass and disease progression in patients with amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 3615-3625.	1.7	10

#	ARTICLE	IF	CITATIONS
19	A Road Map for Remote Digital Health Technology for Motor Neuron Disease. <i>Journal of Medical Internet Research</i> , 2021, 23, e28766.	2.1	16
20	Incidence, Prevalence, and Geographical Clustering of Motor Neuron Disease in the Netherlands. <i>Neurology</i> , 2021, 96, .	1.5	19
21	Portable fixed dynamometry: towards remote muscle strength measurements in patients with motor neuron disease. <i>Journal of Neurology</i> , 2021, 268, 1738-1746.	1.8	8
22	Reconsidering the revised amyotrophic lateral sclerosis functional rating scale for ALS clinical trials. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 569-570.	0.9	4
23	Advancing disease monitoring of amyotrophic lateral sclerosis with the compound muscle action potential scan. <i>Clinical Neurophysiology</i> , 2021, 132, 3152-3159.	0.7	9
24	Pharmacogenetic interactions in amyotrophic lateral sclerosis: a step closer to a cure?. <i>Pharmacogenomics Journal</i> , 2020, 20, 220-226.	0.9	14
25	In pursuit of the normal progressor: the holy grail for ALS clinical trial design?. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 1-2.	1.1	3
26	The rise of innovative clinical trial designs: whatâ€™s in it for amyotrophic lateral sclerosis?. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 3-4.	1.1	1
27	Development and assessment of the inter-rater and intra-rater reproducibility of a self-administration version of the ALSFRS-R. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 75-81.	0.9	41
28	Nerve ultrasound for diagnosing chronic inflammatory neuropathy. <i>Neurology</i> , 2020, 95, e1745-e1753.	1.5	32
29	Quantitative MRI of skeletal muscle in a cross-sectional cohort of patients with spinal muscular atrophy types 2 and 3. <i>NMR in Biomedicine</i> , 2020, 33, e4357.	1.6	31
30	TRICALS: creating a highway toward a cure. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 496-501.	1.1	20
31	Clinical outcomes in multifocal motor neuropathy. <i>Neurology</i> , 2020, 95, e1979-e1987.	1.5	13
32	Muscle strength and motor function in adolescents and adults with spinal muscular atrophy. <i>Neurology</i> , 2020, 95, e1988-e1998.	1.5	44
33	Frequent self-assessments in ALS Clinical Trials: worthwhile or an unnecessary burden for patients?. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2074-2075.	1.7	5
34	Current trends in the clinical trial landscape for amyotrophic lateral sclerosis. <i>Current Opinion in Neurology</i> , 2020, 33, 655-661.	1.8	17
35	<p>Usefulness of a Double-Blind Placebo-Controlled Response Test to Demonstrate Rapid Onset Analgesia with Phenytoin 10% Cream in Polyneuropathy</p>. <i>Journal of Pain Research</i> , 2020, Volume 13, 877-882.	0.8	8
36	A placebo-controlled trial to investigate the safety and efficacy of Penicillin G/Hydrocortisone in patients with ALS (PHALS trial). <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 584-592.	1.1	4

#	ARTICLE	IF	CITATIONS
37	Prognostic value of weight loss in patients with amyotrophic lateral sclerosis: a population-based study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 867-875.	0.9	46
38	Relative hyperventilation in non-ventilated patients with spinal muscular atrophy. <i>European Respiratory Journal</i> , 2020, 56, 2000162.	3.1	2
39	The Distinct Traits of the UNC13A Polymorphism in Amyotrophic Lateral Sclerosis. <i>Annals of Neurology</i> , 2020, 88, 796-806.	2.8	23
40	Nerve ultrasound improves detection of treatment-responsive chronic inflammatory neuropathies. <i>Neurology</i> , 2020, 94, e1470-e1479.	1.5	38
41	Natural history of lung function in spinal muscular atrophy. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 88.	1.2	56
42	Fatigability in spinal muscular atrophy: validity and reliability of endurance shuttle tests. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 75.	1.2	22
43	Population-based analysis of survival in spinal muscular atrophy. <i>Neurology</i> , 2020, 94, e1634-e1644.	1.5	54
44	Human immune globulin 10% with recombinant human hyaluronidase in multifocal motor neuropathy. <i>Journal of Neurology</i> , 2019, 266, 2734-2742.	1.8	4
45	Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 595-604.	1.1	63
46	Implications of spirometric reference values for amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 473-480.	1.1	4
47	Accelerometry for remote monitoring of physical activity in amyotrophic lateral sclerosis: a longitudinal cohort study. <i>Journal of Neurology</i> , 2019, 266, 2387-2395.	1.8	39
48	Loss of appetite is associated with a loss of weight and fat mass in patients with amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 497-505.	1.1	38
49	Natural course of scoliosis and lifetime risk of scoliosis surgery in spinal muscular atrophy. <i>Neurology</i> , 2019, 93, e149-e158.	1.5	45
50	Evidence for a multimodal effect of riluzole in patients with ALS?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1183-1184.	0.9	22
51	Two heads are better than one: benefits of joint models for ALS trials. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1071-1072.	0.9	6
52	Statins do not increase risk of polyneuropathy. <i>Neurology</i> , 2019, 92, e2136-e2144.	1.5	7
53	Aerobic Exercise Therapy in Ambulatory Patients With ALS: A Randomized Controlled Trial. <i>Neurorehabilitation and Neural Repair</i> , 2019, 33, 153-164.	1.4	19
54	Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2019-320998.	0.9	14

#	ARTICLE	IF	CITATIONS
55	Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. <i>Neurology</i> , 2019, 92, .	1.5	66
56	Increasing the efficiency of clinical trials in neurodegenerative disorders using group sequential trial designs. <i>Journal of Clinical Epidemiology</i> , 2018, 98, 80-88.	2.4	8
57	Hypermetabolism in ALS is associated with greater functional decline and shorter survival. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1016-1023.	0.9	177
58	Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. <i>Lancet Neurology</i> , The, 2018, 17, 423-433.	4.9	342
59	Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 156-161.	0.9	62
60	C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 281.1-281.	0.9	33
61	Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. <i>Neurology</i> , 2017, 89, 1915-1922.	1.5	82
62	Effect of Individual Surgeons and Anesthesiologists on Operating Room Time. <i>Anesthesia and Analgesia</i> , 2016, 123, 445-451.	1.1	29
63	Comment: Plateaus and reversals in ALS disease course or limitations of trial design?. <i>Neurology</i> , 2016, 86, 811-811.	1.5	1
64	Novel Application of Postmortem CT Angiography for Evaluation of the Intracranial Vascular Anatomy in Cadaver Heads. <i>American Journal of Roentgenology</i> , 2015, 205, 1276-1280.	1.0	6